Bayer Consumer Chief Identifies 'Root Causes' Of Slump, Initiates Growth 'Fix'
Executive Summary
Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."
You may also be interested in...
Coppertone, Dr. Scholl’s On The Block As Bayer Narrows Consumer Health Focus
Bayer will sell Coppertone sunscreen and Dr. Scholl’s foot care brands to focus on growing its core consumer health brands. Although the plan represents ‘failure” in turning around sales for both brands, it is a ‘sensible’ move, say analysts.
Bayer’s “challenging year” persisting
What is proving to be a “challenging year” for Bayer Consumer Health has continued into the second quarter of 2018, according to the German group’s chief executive officer Werner Baumann.
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.